[SCHEDULE 13G] Protagonist Therapeutics, Inc SEC Filing

Rhea-AI Filing Summary

State Street Corporation filed a Schedule 13G reporting beneficial ownership of common stock of Protagonist Therapeutics, Inc. The filing states State Street beneficially owns 3,207,774 shares, representing 5.2% of the outstanding class. The report shows 0 shares as sole voting power and sole dispositive power, with 3,033,685 shares of shared voting power and 3,207,774 shares of shared dispositive power.

The filing lists several State Street entities through which the position is held, including SSGA Funds Management, Inc., State Street Bank and Trust Company, and multiple State Street Global Advisors entities. The submission includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Positive

• Reporting person holds 3,207,774 shares of PTGX, representing a material 5.2% ownership stake
• Filing expressly states holdings are in the ordinary course of business and not held to change control

Negative

• Reporting person reports 0 sole voting power and 0 sole dispositive power, indicating no direct control over the issuer

Insights

Financial Analyst

TL;DR: State Street reports a material passive stake of 5.2% (3.21M shares) in PTGX with shared voting and dispositive power.

State Street's filing discloses a >5% position, which is material from a disclosure standpoint but does not by itself indicate control. The split showing 0 sole voting/dispositive power and significant shared powers implies custody or pooled-management arrangements common for large custodial/investment managers. For investors, the key facts are the absolute size of the holding (3,207,774 shares) and the percentage (5.2%), both explicitly reported in the filing.

Corporate Governance Expert

TL;DR: This is a routine institutional Schedule 13G filing showing substantial passive ownership without sole control.

The filing identifies multiple State Street subsidiaries as relevant holders, indicating the position is held through institutional vehicles rather than a single controlling entity. The certification that the securities are held in the ordinary course and not to influence control is consistent with a Rule 13G passive disclosure. Material governance impact is limited given the absence of sole voting or dispositive power.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

PROTAGONIST THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

74366E102

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74366E102

1

Names of Reporting Persons

STATE STREET CORPORATION

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,033,685.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,207,774.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,207,774.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PROTAGONIST THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 7707 GATEWAY BLVD SUITE 140 , NEWARK, CALIFORNIA, 94560
Item 2.
(a)	Name of person filing: STATE STREET CORPORATION;
(b)	Address or principal business office or, if none, residence: ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
(c)	Citizenship: MA
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 74366E102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3207774.00
(b)	Percent of class: 5.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,033,685
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,207,774
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. NOT APPLICABLE
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET BANK AND TRUST COMPANY (BK);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. NOT APPLICABLE
Item 9.	Notice of Dissolution of Group.
	Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. NOT APPLICABLE

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

STATE STREET CORPORATION

Signature:	ELIZABETH SCHAEFER
Name/Title:	SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
Date:	08/08/2025

FAQ

How many PTGX shares does State Street report owning?

3,207,774 shares, representing 5.2% of the outstanding common stock as reported in the Schedule 13G.

Does State Street have voting control over PTGX?

The filing reports 0 shares of sole voting power and 3,033,685 shares of shared voting power, so no sole voting control is indicated.

What dispositive power does State Street report for PTGX?

The filing reports 0 sole dispositive power and 3,207,774 shared dispositive power over the reported shares.

Through which subsidiaries does State Street hold the PTGX position?

The filing identifies subsidiaries including SSGA Funds Management, Inc., State Street Bank and Trust Company, and multiple State Street Global Advisors entities as relevant holders.

Was the position acquired to influence control of Protagonist Therapeutics (PTGX)?

The filing includes a certification stating the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.